Save information for later
Sign Up

Learn About Cramp-Fasciculation Syndrome

Who are the top Cramp-Fasciculation Syndrome Local Doctors?
Elite in Cramp-Fasciculation Syndrome
Elite in Cramp-Fasciculation Syndrome
Munich, BY, DE 

Benedikt Schoser practices in Munich, Germany. Mr. Schoser is rated as an Elite expert by MediFind in the treatment of Cramp-Fasciculation Syndrome. His top areas of expertise are Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, Pompe Disease, and Thymectomy.

Elite in Cramp-Fasciculation Syndrome
Elite in Cramp-Fasciculation Syndrome
Brussels, BRU, BE 

Michel Toussaint practices in Brussels, Belgium. Mr. Toussaint is rated as an Elite expert by MediFind in the treatment of Cramp-Fasciculation Syndrome. His top areas of expertise are Cramp-Fasciculation Syndrome, Duchenne Muscular Dystrophy, Swallowing Difficulty, and Becker Muscular Dystrophy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Cramp-Fasciculation Syndrome
Elite in Cramp-Fasciculation Syndrome

Krankenanstalt Rudolfstiftung

Vienna, AT 

C Stollberger practices in Vienna, Austria. Stollberger is rated as an Elite expert by MediFind in the treatment of Cramp-Fasciculation Syndrome. Their top areas of expertise are Cardiomyopathy, Endocardial Fibroelastosis, Cramp-Fasciculation Syndrome, Heart Transplant, and Embolectomy.

What are the latest Cramp-Fasciculation Syndrome Clinical Trials?
Environmental Risk Factors for the Anti-Synthetase Syndrome

Background: * Like other complex diseases, autoimmune diseases are the result of numerous causes, including genetic and environmental factors. Some researchers believe that people who are susceptible to autoimmune disorders develop them when the body reacts to environmental or other factors by creating white blood cells that attack the body s own tissues, which then progresses to autoimmune diseases. These im...

Match to trials
Find the right clinical trials for you in under a minute
Get started
An Open-label Phase 1b/2 Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

Summary: This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 3 parts, Part A, Part B, i...

Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center